Clinical Trials Logo

Clinical Trial Summary

This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.


Clinical Trial Description

The purpose of this study is to explore genetic factors associated with the development of pulmonary fibrosis. The investigators aim is to identify and explore genetic loci that affect development of pulmonary fibrosis and also explore related environmental exposures. Idiopathic pulmonary fibrosis (IPF) is one of the interstitial lung diseases under the broader umbrella of idiopathic interstitial pneumonias (IIP). The investigators hypothesize that inherited genetic factors are associated with pulmonary fibrosis. To investigate the genetics of pulmonary fibrosis, the investigators plan to enroll individuals with pulmonary fibrosis and their family members. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03478553
Study type Observational
Source University of Colorado, Denver
Contact Rachel Warren
Phone 303-724-8569
Email rachel.warren@cuanschutz.edu
Status Recruiting
Phase
Start date January 18, 2018
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04497831 - Morphine for Dyspnea in Pulmonary Fibrosis Phase 3
Recruiting NCT05119972 - Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 1/Phase 2
Completed NCT01718990 - Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
Completed NCT00162760 - Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide Phase 2
Terminated NCT04589260 - TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis Phase 1
Completed NCT04069143 - A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327 Phase 1
Completed NCT03050255 - Short-term Effects of Supplemental Oxygen in Patients With IPF N/A
Terminated NCT02013700 - Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) Phase 1
Recruiting NCT04598919 - Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis Phase 1/Phase 2
Completed NCT03981094 - A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants Phase 1
Completed NCT02758808 - Pulmonary Fibrosis Foundation Patient Registry
Not yet recruiting NCT05387785 - Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis Phase 1
Recruiting NCT05938920 - Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT02538536 - A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT01371305 - STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Withdrawn NCT03720483 - Inhaled NAC in Treatment of IPF Phase 1/Phase 2
Completed NCT03650075 - To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers Phase 1
Recruiting NCT05975983 - Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03832946 - A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT02874989 - Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial Phase 1